Novo Nordisk A/S

EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial" (2019) Mann J, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR Journal article, Note Health-related quality of life in people with type 2 diabetes participating in the LEADER trial (2019) Nauck MA, Buse JB, Mann J, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A Journal article Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events (2018) Husain M, Bain SC, Mann J, Nauck M, Poulter N, Baeres FMM, Goldman B, et al. Conference contribution Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann J, Nauck MA, Nissen SE, et al. Journal article Animal Models of Rheumatoid Arthritis (I): Pristane-Induced Arthritis in the Rat (2016) Tuncel J, Haag S, Hoffmann M, Yau ACY, Hultqvist M, Olofsson P, Backlund J, et al. Journal article LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial (2016) Petrie JR, Marso SP, Bain SC, Franek E, Jacob S, Masmiquel L, Leiter LA, et al. Journal article Prediction of beam hardening artefacts in computed tomography using Monte Carlo simulations (2015) Thomsen M, Knudsen EB, Willendrup PK, Bech M, Willner M, Pfeiffer F, Poulsen M, et al. Journal article LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations (2015) Daniels GH, Hegedus L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann J, et al. Journal article